(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More
(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More
(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More
(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours. Read More
(Alliance News) - Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China's national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country's first-ever commercial insurance drug list. Read More
(Alliance News) - Hutchmed China Ltd on Wednesday said patient enrolment has been completed for its phase 3 Saffron trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients, with topline results expected in the first half of 2026. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said Chief Executive Officer Weiguo Su will take a leave of absence for health reasons. Read More
(Alliance News) - Hutchmed China Ltd on Wednesday said it has completed patient enrollment of Sanovo, a phase three trial of Orpathys and Tagrisso. Read More
(Alliance News) - Hutchmed China Ltd on Thursday reported a jump in profit during the first half of its current financial year, and forecasts a full-year decline in its key Oncology/Immunology segment. Read More
(Alliance News) - Hutchmed China Ltd on Monday said its combination therapy for a specific form of advanced lung cancer significantly delayed disease progression compared to chemotherapy, based on phase III trial data presented at a major oncology conference. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - London's FTSE 100 opened higher on Tuesday following the long Easter weekend, as the gold price rallies in response to a weakening US dollar and efforts by US President Donald Trump to potentially force out the Federal Reserve chair. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said it has completed patient enrolment for a phase II registration trial of savolitinib, targeting gastric cancer in patients with MET gene amplification. Read More
(Alliance News) - London's FTSE 100 was called higher on Tuesday following the long Easter weekend as the gold price reaches a new record high, while US investors remain cautious amid US President Donald Trump's threats to oust the Federal Reserve chair. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - The new drug application for Tazverik has been granted conditional approval by the National Medical Products Administration in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with the EZH2 gene mutation who have received at least two prior systemic therapies. Approval was based on positive results from a phase II bridging study in China, and clinical studies conducted by Epizyme Inc, a subsidiary of Paris-based pharmaceutical firm Ipsen SA. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More